Design and validation of a histological scoring system for nonalcoholic fatty liver disease

By D. Kleiner, E. Brunt, M. V. Van Natta, Cynthia Behling, M. Contos, O. Cummings, L. Ferrell, Yao‐Chang Liu, M. Torbenson, A. Unalp-arida and 3 more. Hepatology, 2005

10,109 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/311ec4a51b7a8b823424c1ead9963141da204fde

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. B. Neuschwander‐Tetri
2. Gerald I. Shulman
3. Jeffrey I. Gordon
4. R. Loomba
5. E. Bugianesi
6. D. Clegg
7. B. Palmer

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. Gerald I. Shulman
4. A. Sanyal
5. K. Cusi
6. Q. Anstee
7. Asociacion Latinoamericana para el Estudio del Higado
8. C. Day

In Hepatology

1. Z. Younossi
2. M. Rinella
3. R. Loomba
4. Asociacion Latinoamericana para el Estudio del Higado
5. Gerald I. Shulman
6. Q. Anstee
7. K. Cusi
8. A. McCullough

Citations in the corpus

• Cellular senescence drives age-dependent hepatic steatosis (2017, positive): “The grade of steatosis (0–3), disease activity, including semi-quantification of lobular inflammation and hepatocyte ballooning, and stage of fibrosis (0–4) were assessed according to Kleiner et al. 48 and Bedossa et al. 49 .”
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017, methodology): “For this analysis, it was estimated that 20-25% of those with NAFLD currently have NASH and that about 20% of those with NASH have ≥ F3 fibrosis (21-25).”
• The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. (2006, result): “The pathological diagnosis of NASH after liver biopsy was in accordance with Kleiner et al. (2005).”
• The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota (2016, methodology): “Steatosis, lobular inflammation, ballooning, and liver fibrosis were semiquantitatively evaluated according to the NASH CRN scoring system((19)): F0 5 no fibrosis; F1 5 perisinusoidal or portal/periportal fibrosis; F2 5 perisinusoidal and portal/periportal fibrosis; F3 5 bridging fibrosis; and F4 5 ”
• Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research (2006, background): “The features of true steatohepatitis that should include ballooning hepatocyte degeneration in addition to simply fatty change and an inflammatory infiltrate (Kleiner et al. 2005), are less frequently demonstrated in these models.”
• Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients (2012, methodology): “NAFLD is characterized by macrovesicular steatosis; indeed, the presence of steatosis in at least 5% of hepatocytes is generally accepted as a definition.(9,10) Nonalcoholic steatohepatitis (NASH), a subgroup of NAFLD, deserves particular attention because of the risk for of evolution to cirrhosis.”